Boehringer Ingelheim's Pradaxa to garner bigger sales in Korea

Pradaxa (dabigatran etexilate), which was approved by the Korea Food and Drug Administration on February 18, will hit the domestic blood thinning products market, according to market experts.

Pradaxa is an anticoagulant that acts by inhibiting thrombin, an enzyme in the blood that is involved in blood clotting. The safety and efficacy of Pradaxa were studied in a clinical trial comparing Pra...